is the tirzepatide shortage over Eli Lilly joins FDA as Defendant in Lawsuit FDA Says Shortage of GLP-1

Jastreboff AM, Aronne LJ, Ahmad NN et al

Utilizing genetic data to customize health advice enables you to start a path toward improved wellness and preventive care against diseases

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study

What color is FDA-approved tirzepatide The simplest answer first

The SURPASS clinical trial programme, which evaluated tirzepatide's safety and efficacy across thousands of participants, did not identify peripheral neuropathy or paraesthesia as a significant adverse event attributable to the medication, as summarised in the European Medicines Agency's European Public Assessment Report (EPAR)